Italia markets closed

Celltrion, Inc. (068270.KS)

KSE - KSE Prezzo differito. Valuta in KRW.
Aggiungi a watchlist
183.800,00-400,00 (-0,22%)
Alla chiusura: 03:30PM KST

Celltrion, Inc.

23 Academy-ro
Yeonsu-gu
Incheon
South Korea
82 3 2850 5000
https://www.celltrion.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Hyong-Gi KimCEO & Internal DirectorN/DN/D1965
Mr. Woo-Sung KeeCEO & Internal DirectorN/DN/D1961
Jin-seok SeoCo-CEO & Inside Co-Chairman of the BoardN/DN/DN/D
Mr. Stephen YeumFounderN/DN/DN/D
Mr. Min-Cheol ShinDirector of FinanceN/DN/D1971
Mr. Ji-Hoon ChoiDirector of Legal AffairsN/DN/D1971
Gli importi risalgono al giorno 31 dicembre 2011 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in KRW.

Descrizione

Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 3 clinical trial; CT-P17 for the treatment of autoimmune diseases which is in phase 3 clinical trial; CT-P16 for the treatment of non-small cell lung cancer and colon cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 3 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P47 for the treatment of rheumatoid arthritis, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. The company was founded in 2002 and is headquartered in Incheon, South Korea.

Governance aziendale

L'ISS Governance QualityScore di Celltrion, Inc. al 1 marzo 2024 è 3. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 4; diritti degli azionisti: 4; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.